These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25182125)

  • 61. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
    Aldughaim MS; Muthana M; Alsaffar F; Barker MD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.
    Huober J; Schoch O; Templeton A; Spirig C; Thürlimann B
    Chemotherapy; 2010; 56(1):69-70. PubMed ID: 20145394
    [No Abstract]   [Full Text] [Related]  

  • 63. Mapping the Technological Knowledge Landscape: The Case of Epigenetics.
    Song CH; Yoon J; Ko N; Han JW
    Recent Pat Anticancer Drug Discov; 2016; 11(4):424-433. PubMed ID: 27557814
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx/Doxil).
    Grenier N; Lebel V; Gill M; Mullen T; Mitchinson K; Sebborn K; Pouliot JF
    Can Oncol Nurs J; 2007; 17(3):133-40. PubMed ID: 17944313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Translation of knowledge on cervical cancer: is there a gap between research on causes and research on patient care?].
    Fajardo-Ortiz D; Ochoa H; García L; Castaño V
    Cad Saude Publica; 2014 Feb; 30(2):415-26. PubMed ID: 24627068
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
    Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
    Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[
    Wu CY; Tang JH; Chan PC; Li JJ; Lin MH; Shen CC; Liu RS; Wang HE
    Mol Imaging Biol; 2017 Jun; 19(3):408-420. PubMed ID: 27730471
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice.
    Andriyanov AV; Portnoy E; Koren E; Inesa S; Eyal S; Goldberg SN; Barenholz Y
    J Control Release; 2017 Jul; 257():2-9. PubMed ID: 28215670
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis.
    Ananth P; Werger A; Voss S; Rodriguez-Galindo C; Janeway KA
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27905688
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Chemotherapy of AIDS-Related Kaposi's Sarcoma: A Meta-Analysis.
    Liu R; Zhou J; Yang S; Zhang Z
    Am J Ther; 2018; 25(6):e719-e721. PubMed ID: 29509553
    [No Abstract]   [Full Text] [Related]  

  • 71. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
    Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
    Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review.
    Ishihara A; Hatakeyama S; Suzuki J; Amano Y; Sasahara T; Toshima M; Morisawa Y
    BMC Infect Dis; 2019 Oct; 19(1):848. PubMed ID: 31615436
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pulsed-wave low-dose ultrasound hyperthermia selectively enhances nanodrug delivery and improves antitumor efficacy for brain metastasis of breast cancer.
    Wu SK; Chiang CF; Hsu YH; Liou HC; Fu WM; Lin WL
    Ultrason Sonochem; 2017 May; 36():198-205. PubMed ID: 28069201
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature.
    Maeda M; Mabuchi S; Matsumoto Y; Hisamatsu T; Ohashi H; Kimura T
    Eur J Gynaecol Oncol; 2011; 32(5):542-6. PubMed ID: 22053671
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Knowledge translation in healthcare: Incorporating theories of learning and knowledge from the management literature.
    Oborn E; Barrett M; Racko G
    J Health Organ Manag; 2013; 27(4):412-31. PubMed ID: 24003630
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
    Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
    ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.